Lead
Generation
Lead
Optimisation
Pre-clinical
POC
CTA / IND Phase I Phase II

Oncology

Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor

Redx is developing novel inhibitors of Porcupine, a key component of the Wnt cancer stem cell pathway. Potential opportunities exist for the treatment of gastric, biliary and pancreatic cancer also in combination with checkpoint inhibitors to enhance clinical response rates in a range of solid tumour types.

BTK inhibitor
BTK inhibitor
BTK inhibitor

Redx is developing best-in-class reversible inhibitors of BTK for the treatment of Ibrutinib resistant chronic lymphocytic leukaemia.

Pan-Raf inhibitor
Pan-Raf inhibitor
Pan-Raf inhibitor

Redx is developing novel small molecule therapeutics with combined activity against different Raf isoforms. These novel compounds target mechanisms of resistance associated with existing MAPK pathway inhibitors in conditions such as colorectal cancer.

AstraZeneca Collaboration
AstraZeneca Collaboration
AstraZeneca Collaboration

Redx and AstraZeneca are collaborating on an undisclosed target for cancer therapy.

SHP2
SHP2

Redx is developing novel SHP2 inhibitors for the treatment of several difficult to treat solid tumour types.

Immunology

Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor

Redx is developing potent porcupine inhibitors for the treatment of a range of fibrotic diseases.

BTK inhibitor
BTK inhibitor
BTK inhibitor

Redx is developing best-in-class BTK inhibitors for the treatment of autoimmune and inflammatory disorders such as rheumatoid arthritis, lupus and Sjögren's syndrome.

Soft Pan-ROCK
Soft Pan-ROCK
Soft Pan-ROCK

Redx is developing highly potent locally acting ROCK inhibitors for the treatment of fibrosis associated with IBD.

ROCK2
ROCK2

Redx is developing best-in-class selective inhibitors of ROCK2 for the treatment of a range of fibrotic diseases.

Lead
Generation
Lead
Optimisation
Pre-clinical
POC
CTA / IND Phase I Phase II

Last updated 17/05/17